相关实验视频

Updated: Mar 6, 2026

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

遗传学是否有助于指导持久性心房的患者的废除策略?

Michael W Lim1,2,3,4, Peter M Kistler2,3,4, Annie G Curtin2,4

  • 1Department of Cardiology, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Journal of cardiovascular electrophysiology
|March 4, 2026
PubMed
概括

将后壁隔离 (PWI) 添加到肺静脉隔离 (PVI) 中,并没有改善持久性心房 (AF) 患者的废除结果,这些患者的AF多原风险得分 (PRS) 高. 这些发现表明,单独PVI对于这个患者群体来说就足够了.

关键词:
持续的心房动 持续的心房动多基因风险评分多基因风险评分.后壁隔离器的隔离方式

更多相关视频

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K
Electrophysiological Assessment of Murine Atria with High-Resolution Optical Mapping08:19

Electrophysiological Assessment of Murine Atria with High-Resolution Optical Mapping

Published on: February 22, 2018

10.6K

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
547